A review of existing neonatal hyperbilirubinemia guidelines in Indonesia

• Main Authors: Mahendra Tri Arif Sampurna, -, Kian Djien Liem, -, Danny Chandra Pratama, -, Novita Oktaviana, -, Achmad Januar Er Putra, -, Rahmi Zakiyah, -, Visuddho, -, Risa Etika, -, Kartika Dharma Handayani, -, Martono Tri Utomo, -, Dina Angelica, -, Wurry Ayuningtyas, -, Toto Wisnu Hendrarto, -, Rinawati Rohsiswatmo, -, Setya Wandita, -, Risma Karina Kaban, -, Jordy Maulana Ahmad, -
• Format: Article PeerReviewed
• Language: English; English; English
• Published: Taylor & Francis 2022
• Subjects: R Medicine (General); RJ Pediatrics
• Online Access: https://repository.unair.ac.id/126978/1/Artikel%201.pdf; https://repository.unair.ac.id/126978/2/FORM%20KARIL%201.pdf; https://repository.unair.ac.id/126978/3/Similarity%201.pdf; https://repository.unair.ac.id/126978/; https://f1000research.com/articles/11-1534; https://doi.org/10.12688/f1000research.110550.1
• Institution: Universitas Airlangga

Background: Neonatal hyperbilirubinemia is one of the most common conditions for neonate inpatients. Indonesia faces a major challenge in which different guidelines regarding the management of this condition were present. This study aimed to compare the existing guidelines regarding prevention, diagnosis, treatment and monitoring in order to create the best recommendation for a new hyperbilirubinemia guideline in Indonesia. Methods: Through an earlier survey regarding adherence to the neonatal hyperbilirubinemia guideline, we identified that three main guidelines are being used in Indonesia. These were developed by the Indonesian Pediatric Society (IPS), the Ministry of Health (MoH), and World Health Organization (WHO). In this study, we compared factors such as prevention, monitoring, methods for identifying, risk factors in the development of neonatal jaundice, risk factors that increase brain damage, and intervention treatment threshold in the existing guidelines to determine the best recommendations for a new guideline. Results: The MoH and WHO guidelines allow screening and treatment of hyperbilirubinemia based on visual examination (VE) only. Compared with the MoH and WHO guidelines, risk assessment is comprehensively discussed in the IPS guideline. The MoH guideline recommends further examination of an icteric baby to ensure that the mother has enough milk without measuring the bilirubin level. The MoH guideline recommends referring the baby when it looks yellow on the soles and palms. The WHO and IPS guidelines recommend combining VE with an objective measurement of transcutaneous or serum bilirubin. The threshold to begin phototherapy in the WHO guideline is lower than the IPS guideline while the exchange transfusion threshold in both guidelines are comparably equal. Conclusions: The MoH guideline is outdated. MoH and IPS guidelines are causing differences in approaches to the management hyperbilirubinemia. A new, uniform guideline is required.